ImmuneWalk Therapeutics is a private clinical-stage company focused on development of novel therapies for chronic inflammatory diseases.

The company's Monocyte Targeting Technology (MTT) is designed to selectively block the migration of monocytes from the blood stream into inflamed tissues.

With clear disease-modifying activity in models of Multiple Sclerosis, Rheumatoid Arthritis, Inflammatory Bowel Disease and Non- Alcoholic Steatohepatitis, in addition to proof-of-concept from patient’s cells, The company is advancing its solution (IW-601) to a Ph1 clinical trial.